![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MRPS9 |
Gene summary for MRPS9 |
![]() |
Gene information | Species | Human | Gene symbol | MRPS9 | Gene ID | 64965 |
Gene name | mitochondrial ribosomal protein S9 | |
Gene Alias | MRP-S9 | |
Cytomap | 2q12.1 | |
Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P82933 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64965 | MRPS9 | LZE2T | Human | Esophagus | ESCC | 5.17e-04 | 5.94e-01 | 0.082 |
64965 | MRPS9 | LZE4T | Human | Esophagus | ESCC | 5.56e-12 | 2.26e-01 | 0.0811 |
64965 | MRPS9 | LZE24T | Human | Esophagus | ESCC | 3.46e-11 | 2.78e-01 | 0.0596 |
64965 | MRPS9 | LZE6T | Human | Esophagus | ESCC | 3.67e-04 | 1.19e-01 | 0.0845 |
64965 | MRPS9 | P1T-E | Human | Esophagus | ESCC | 8.65e-05 | 2.98e-01 | 0.0875 |
64965 | MRPS9 | P2T-E | Human | Esophagus | ESCC | 1.56e-29 | 4.57e-01 | 0.1177 |
64965 | MRPS9 | P4T-E | Human | Esophagus | ESCC | 7.77e-26 | 7.94e-01 | 0.1323 |
64965 | MRPS9 | P5T-E | Human | Esophagus | ESCC | 3.08e-24 | 5.14e-01 | 0.1327 |
64965 | MRPS9 | P8T-E | Human | Esophagus | ESCC | 4.63e-20 | 2.32e-01 | 0.0889 |
64965 | MRPS9 | P9T-E | Human | Esophagus | ESCC | 3.45e-15 | 3.18e-01 | 0.1131 |
64965 | MRPS9 | P10T-E | Human | Esophagus | ESCC | 1.88e-33 | 5.74e-01 | 0.116 |
64965 | MRPS9 | P11T-E | Human | Esophagus | ESCC | 3.44e-09 | 4.02e-01 | 0.1426 |
64965 | MRPS9 | P12T-E | Human | Esophagus | ESCC | 2.36e-28 | 4.86e-01 | 0.1122 |
64965 | MRPS9 | P15T-E | Human | Esophagus | ESCC | 1.29e-27 | 6.48e-01 | 0.1149 |
64965 | MRPS9 | P16T-E | Human | Esophagus | ESCC | 3.07e-21 | 3.82e-01 | 0.1153 |
64965 | MRPS9 | P17T-E | Human | Esophagus | ESCC | 3.31e-04 | 2.58e-01 | 0.1278 |
64965 | MRPS9 | P20T-E | Human | Esophagus | ESCC | 2.14e-14 | 3.67e-01 | 0.1124 |
64965 | MRPS9 | P21T-E | Human | Esophagus | ESCC | 4.57e-48 | 9.82e-01 | 0.1617 |
64965 | MRPS9 | P22T-E | Human | Esophagus | ESCC | 3.89e-26 | 3.23e-01 | 0.1236 |
64965 | MRPS9 | P23T-E | Human | Esophagus | ESCC | 6.98e-23 | 5.72e-01 | 0.108 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00427697 | Esophagus | ESCC | DNA damage response, detection of DNA damage | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
GO:00427693 | Liver | Cirrhotic | DNA damage response, detection of DNA damage | 10/4634 | 13/18723 | 1.14e-04 | 1.14e-03 | 10 |
GO:004276911 | Liver | HCC | DNA damage response, detection of DNA damage | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
GO:00427696 | Oral cavity | OSCC | DNA damage response, detection of DNA damage | 11/7305 | 13/18723 | 1.02e-03 | 5.29e-03 | 11 |
GO:004276913 | Oral cavity | LP | DNA damage response, detection of DNA damage | 9/4623 | 13/18723 | 8.93e-04 | 7.64e-03 | 9 |
GO:00427698 | Skin | cSCC | DNA damage response, detection of DNA damage | 10/4864 | 13/18723 | 1.78e-04 | 1.50e-03 | 10 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MRPS9 | SNV | Missense_Mutation | novel | c.476N>T | p.Tyr159Phe | p.Y159F | P82933 | protein_coding | tolerated(0.15) | probably_damaging(0.996) | TCGA-BA-6868-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
MRPS9 | SNV | Missense_Mutation | novel | c.63N>T | p.Arg21Ser | p.R21S | P82933 | protein_coding | tolerated_low_confidence(0.09) | benign(0.01) | TCGA-CN-6992-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
MRPS9 | SNV | Missense_Mutation | novel | c.14N>A | p.Cys5Tyr | p.C5Y | P82933 | protein_coding | deleterious_low_confidence(0.02) | benign(0.088) | TCGA-CN-A63U-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MRPS9 | insertion | Frame_Shift_Ins | novel | c.559_560insA | p.Thr189AsnfsTer14 | p.T189Nfs*14 | P82933 | protein_coding | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
MRPS9 | SNV | Missense_Mutation | rs778158656 | c.1016N>T | p.Ala339Val | p.A339V | P82933 | protein_coding | tolerated(0.06) | possibly_damaging(0.675) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
MRPS9 | SNV | Missense_Mutation | rs750727078 | c.1123N>T | p.Arg375Cys | p.R375C | P82933 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MRPS9 | SNV | Missense_Mutation | c.825A>C | p.Lys275Asn | p.K275N | P82933 | protein_coding | tolerated(0.38) | benign(0.056) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MRPS9 | deletion | Frame_Shift_Del | c.632delN | p.Lys212AsnfsTer5 | p.K212Nfs*5 | P82933 | protein_coding | TCGA-BR-4256-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
MRPS9 | SNV | Missense_Mutation | novel | c.1162N>A | p.Arg388Ser | p.R388S | P82933 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-ET-A39R-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |